The co-listed chemical series 3-chloro-1,2-propanediol, (R)-(-)-epichlorohydrin, (S)-(+)-epichlorohydrin, and (R)-(+)-propylene carbonate is frequently encountered in sourcing documentation as a single line item for tablet, capsule, granule, and injection development. The designation is not a single chemical entity. 3-Chloro-1,2-propanediol CAS 96-24-2 is a chlorinated diol of molecular weight 110.54 g/mol; the two epichlorohydrins are enantiomeric C3 epoxides; (R)-(+)-propylene carbonate CAS 14611-64-2 is a chiral cyclic carbonate. The differentiation is operationally decisive: 3-chloro-1,2-propanediol is controlled as a potential process impurity or reference material under ICH M7 when present as an impurity, while enantiomeric epichlorohydrins are reactive chiral building blocks and propylene carbonate is a solvent or processing aid with residual solvent obligations under ICH Q3C and USP 467. A single technical grade or pharma grade designation therefore does not convert all four substances into active pharmaceutical ingredients, and the route-specific quality risks differ.

Specification Boundary for 3-Chloro-1,2-propanediol in Oral Solid Dose Manufacturing

For tablet and capsule applications, 3-chloro-1,2-propanediol is not a drug substance; it is a process impurity and reference standard whose acceptance limit depends on the maximum daily dose, route, and toxicological classification. Routine control uses gas chromatography with flame ionization detection after acetylation or trimethylsilyl derivatization. The neat reference material is commonly specified at assay ≥ 98.0 % by GC-FID, but the pharmaceutical specification is derived from the finished dosage form impurity threshold, not from the neat product assay. Because ICH M7 applies a threshold of toxicological concern of 1.5 µg/day for mutagenic impurities in the absence of substance-specific data, and because 3-chloro-1,2-propanediol is a chloropropanol contaminant with toxicological concern in food matrices, early development batches require an analytical limit of quantification below the calculated allowable intake. Published data for this specific tablet and capsule configuration is limited; control strategies are therefore transferred from food-contact methods and from general ICH M7 risk assessment rather than from a dedicated API monograph.

Within the chiral epichlorohydrin supply chain, the (R)-(-)-enantiomer CAS 51594-55-9 and the (S)-(+)-enantiomer CAS 67843-74-7 are used as electrophilic C3 building blocks for β-amino alcohol and glycidyl ether intermediates. A single-enantiomer epichlorohydrin is not an API; it is a starting material whose chiral purity must be preserved through the ring-opening step. A jacketed reactor with controlled addition of aqueous sodium hydroxide or an amine nucleophile is used because the epoxide ring opens exothermically. The difference between the two enantiomers is not a minor mirror-image formality; the downstream diastereomeric ratio in a tablet or injectable intermediate depends on the starting enantiomer. Purchase specifications for pharmaceutical building blocks are often set at ≥ 98.0 % ee by chiral GC or HPLC, but the actual limit must be justified from the final chiral purity of the drug substance, not from an arbitrary starting-material number. Racemic epichlorohydrin cannot be substituted without revalidating the downstream crystallization and chiral purity of the finished dosage form.

Why Do Injectable Routes Require Enantiomeric Epichlorohydrin Purity Data Before Capsule Formulation?

Parenteral administration removes gastrointestinal first-pass metabolism and reduces the dilution space available in oral solid dose manufacturing. Residual epichlorohydrin in injectable formulations is controlled by the same reactive endpoint logic used for genotoxic impurities under ICH M7, but the allowable daily intake may be lower because the route and treatment duration can alter exposure. If the source material is labelled only as “epichlorohydrin” without the (R)-(-)- or (S)-(+)- descriptor, the specification has no chiral identity, and the ring-opened diastereomeric impurity profile cannot be predicted. For an injectable route, release documentation should include enantiomeric excess by chiral chromatography, residual epichlorohydrin by headspace GC or LC-MS, and absence of polymeric glycidyl ether by-products. Sterile filtration of a solution containing trace epichlorohydrin does not remove the dissolved impurity; terminal sterilization by autoclaving at 121 °C may open the epoxide ring in chloride-containing aqueous media and convert the target enantiomer into 3-chloro-1,2-propanediol or the corresponding diol, altering the safety profile. This is a critical process conflict: heat sterilization can destroy the residual chiral epoxide while generating a chloropropanol impurity that must then be controlled.

For tablet, capsule, and granule unit operations, the combined use of (R)-(+)-propylene carbonate as a binder solvent and 3-chloro-1,2-propanediol as an impurity marker demands that drying parameters be set below the thermal formation window of chloropropanols. A high-shear wet granulator with impeller tip speed 5–12 m/s and a fluid-bed dryer inlet air temperature of 60–80 °C is typical for solvent-based granulation, but the presence of sodium chloride or hydrochloride salts in the formulation may require lower inlet temperatures. Dry blending in a V-blender or bin blender does not generate sufficient shear to open the epoxide ring; however, wet granulation with pregelatinized starch and water can hydrolyze propylene carbonate to propylene glycol and carbon dioxide under acidic pH. The choice of tablet, capsule, or granule intermediate influences residual solvent removal efficiency: a capsule-filled powder may retain residual propylene carbonate more than a compressed tablet because the compression step increases surface-to-volume ratio and facilitates evaporative loss during subsequent coating or curing. Yet residual epichlorohydrin in a capsule may be less thermally exposed than in a tablet dried at 80 °C for 30 min, making the route-specific risk assessment non-linear.

Propylene Carbonate Hydrolytic Instability and Residual Solvent Limits

(R)-(+)-Propylene carbonate CAS 14611-64-2 has molecular weight 102.09 g/mol, density 1.204 g/mL at 20 °C, and boiling point 242 °C. It is a polar aprotic solvent with viscosity 2.5 mPa·s at 25 °C and dielectric constant 64.9. It is used in oral and injectable processing, but it is not inert in aqueous high-pH or low-pH vehicles. At acidic pH, the cyclic carbonate hydrolyzes to (R)-propylene glycol and carbon dioxide; in alkaline solution, the same hydrolysis proceeds via nucleophilic hydroxide attack at the carbonyl carbon. This reactivity creates a residual solvent limit that is coupled to the hydrolytic degradation product. ICH Q3C and USP 467 residual solvent testing may be applied to propylene carbonate when it is used in the manufacturing process; if the formulation vehicle itself contains propylene carbonate, the limit is set under an excipient monograph or a safety data package rather than as a Class 2 residual solvent. The chiral descriptor is relevant because the hydrolysis product (R)-propylene glycol has its own toxicological and compendial status distinct from racemic propylene glycol. Injectable manufacture should use closed stainless-steel vessels with nitrogen overlay because propylene carbonate is hygroscopic and can absorb water from air, leading to slow hydrolysis before sterilization.

When Tablet Granulation Replaces Capsule Blending Without Revalidation of Residual Solvent Limits

The substitution of tablet granulation for capsule blending using the same supplier grade of this multi-component listing requires revalidation of residual solvent levels because the unit operations are not equivalent. In capsule blending, the drug substance and excipients are mixed in a bin blender at low shear; in tablet granulation, the same material is exposed to a high-shear granulator and then dried in a fluid-bed dryer. The thermal and mechanical stress can convert residual epichlorohydrin into 3-chloro-1,2-propanediol in the presence of chloride-containing excipients, changing the impurity profile. A process analytical technology method based on near-infrared spectroscopy may be used to monitor propylene carbonate in granules before compression; the calibration model must include a validation range covering 0.1–1.0 % residual solvent. Published data for this specific configuration is limited, but the failure mode is known from drying studies: localized hot spots in a fluid-bed dryer at inlet air temperature above 80 °C can produce non-uniform residual solvent distribution across the granule size fraction. Tablet compression with a rotary press at 200–300 MPa consolidation pressure may not remove residual solvent if the granule surface is sealed by the compression process; a subsequent coating step can trap residual solvent and increase the risk of hydrolytic degradation on storage. Therefore, the same supplier grade cannot be moved across routes without re-qualifying the complete impurity profile.

In comparison with adjacent compounds, racemic epichlorohydrin CAS 106-89-8 differs from the single-enantiomer grades by its optical composition, not by its basic chemical reactivity. Substituting racemic epichlorohydrin for (R)-(-)- or (S)-(+)-epichlorohydrin changes the downstream diastereomeric ratio and may fail chiral purity release testing of the final drug substance. Compared with glycidol CAS 556-52-5, epichlorohydrin has a chlorine leaving group instead of a hydroxyl group; ring opening of glycidol leads to glycerol, while ring opening of epichlorohydrin can lead to 3-chloro-1,2-propanediol. Compared with propylene glycol CAS 57-55-6, propylene carbonate has higher boiling point and aprotic solvent character, but it hydrolyzes to propylene glycol under acidic or alkaline conditions. Compared with glycerol carbonate, the methyl substituent on propylene carbonate alters the hydrolysis rate and the steric environment around the carbonate carbonyl. These differences are not interchangeable formulation edits; they require separate residual impurity, chiral purity, and degradation product methods when the supplier grade is changed.